Pharma firm Amryt appoints new CCO as firm drives sales of Lojuxta at global level
Amryt Pharma has appointed David Allmond as the firm's new Chief Commercial Officer (CCO).
Before joining the company, Allmond worked for Aegerion Pharmaceuticals, where he was President of EMEA and involved in the commercialisation of Lojuxta (lomitapide) the drug used to treat homozygous familial hypercholesterolemia.
In December 2016 Amryt acquired the exclusive rights to sell Lojuxta across the EU and Middle East and North Africa.
CEO Joe Wiley said that Allmond's extensive commercial experience and his knowledge of Lojuxta is welcome.
"David will resume control of the Lojuxta team and is the ideal person to take on responsibility for the commercial development of this business," he said.
"We remain very excited about the potential to increase the numbers of patients on treatment in existing markets and also to open new markets within our territories.”
Prior to Aegerion, Allmond was Corporate Vice President of Global Marketing for Celgene Corporation.
He was previously responsible for EMEA marketing and market access within Celgene. Prior to Celgene, he was Director of Sales and Marketing Effectiveness at Amgen Ltd.
Allmond joins Amryt - which focuses on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases - in a non-board capacity.